Navigation Links
FailSafe PCR 2X PreMix E from EPICENTRE Biotechnologies

ProductsFailSafe PCR 2X PreMix E from EPICENTRE Biotechnologies
Company EPICENTRE Biotechnologies
Item FailSafe PCR 2X PreMix E
Price $35.00
Description 1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System.
Info EPICENTRE BiotechnologiesEPICENTRE Biotechnologies
726 Post Road
Madison, WI 53713
USA
Customer Service: 800-284-8474
Tech Support: 800-284-8474
Fax Number: 608-442-6114
Web Site: http://www.epibio.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. FailSafe PCR System w/choice of 8 PreMix Tubes from EPICENTRE Biotechnologies
2. FailSafe PCR PreMix Selection Kit from EPICENTRE Biotechnologies
3. FailSafe PCR System w/choice of two PreMix Tubes from EPICENTRE Biotechnologies
4. FailSafe PCR 2X PreMix B from EPICENTRE Biotechnologies
5. FailSafe PROBES Real-Time PCR Optimization Kit from EPICENTRE Biotechnologies
6. MasterAmp 2X PCR PreMix F without (NH4)2SO4 from EPICENTRE Biotechnologies
7. GELase LMP Agarose Gel-Digesting Preparation from EPICENTRE Biotechnologies
8. GELase LMP Agarose Gel-Digesting Preparation from EPICENTRE Biotechnologies
9. Vaccinia DNA Topoisomerase I from EPICENTRE Biotechnologies
10. Vaccinia DNA Topoisomerase I from EPICENTRE Biotechnologies
11. GELase LMT Agarose Gel-Digesting Preparation from EPICENTRE Biotechnologies
UBN-1 (C-20)...
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
Human IL-29/IFN-lambda 1 Biotinylated Affinity Purified PAb...
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
Biology Products:
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
(Date:5/21/2013)... method for delivering molecules into single, targeted cells ... technique could find applications in drug delivery, cell ... a technique used to deliver molecules into ... that are caused by exposing them to electric ... cell transfection. (Cell transfection is the introduction of ...
(Date:5/21/2013)... University of Illinois at Chicago College of Medicine will study ... -- its main energy source -- and how changes in ... new $2 million, 4-year grant from the National Heart, Lung ... it uses fuel for energy. These changes may play a ... different in men and women, says E. Douglas Lewandowski, director ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2Do men's and women's hearts burn fuel differently? 2
... raged over whether organic compounds and tiny globules of ... 84001 were processed by living creatures from the Red ... scrutiny ever since. Scientists at the Carnegie Institution's Geophysical ... how material associated with carbonate globules was created using ...
... more than 100 people have been infected with the H5N1 ... the fact that the virus does not spread easily from ... biomedical puzzle. , Now, a study of cells in the ... cells of the system that makes it difficult for the ...
... North America, two types of invasive vines are growing ... populations and bird habitats. , The vines are pale ... to stem the growth of and their steady conquest ... Canada, Cornell University is teaming up with the U.S. ...
Cached Biology News:Relic of life in that Martian meteorite? A fresh look 2Cell barrier shows why bird flu not so easily spread among humans 2Cell barrier shows why bird flu not so easily spread among humans 3CU, USDA team to curb two invasive, poisonous vines 2CU, USDA team to curb two invasive, poisonous vines 3
(Date:5/21/2013)... OXFORD, England , May 22, 2013 ... inhaled, novel drug-only formulation of glycopyrronium bromide designed using ... speciality pharmaceutical company developing a portfolio of inhaled ... 2 clinical study with PSX1002 that will assess its ... range of doses in patients with moderate to severe ...
(Date:5/21/2013)... study led by George Washington University Professor Tianshu ... ice in small droplets is strongly size-dependent, an ... nanoscale. The formation of ice at the nanoscale ... answer also has important implications for climate research ... ice from supercooled water is generally initiated by ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, ... that Genzyme, a Sanofi company and leading biotech company, ... for a multi-use facility in the United States. With ... buildings, this latest order underscores the satisfaction and success ... device improving doorway access control. , “We ...
(Date:5/21/2013)... Md. , May 21, 2013  MacroGenics, ... 1 study of margetuximab (MGAH22), an Fc-modified chimeric ... tumors expressing the HER2 oncoprotein," will be presented ... Society of Clinical Oncology during the Developmental Therapeutics ... 3 at 4:15 – 4:30 PM.  The presentation ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3